Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2009 (2009), Article ID 357093, 4 pages
http://dx.doi.org/10.1155/2009/357093
Research Article

The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation

1Disciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, Brazil
2Laboratorio de Cytogenetica, da Disciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, Brazil
3Fundação Pro-Sangue/ Hemocentro de São Paulo, 05403-000 São Paulo, Brazil

Received 2 July 2009; Accepted 14 August 2009

Academic Editor: Kazuhiko Yamada

Copyright © 2009 Monika Conchon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We describe the response of imatinib as lifesaving treatment of chronic myeloid leukemia (CML) relapse in seven patients who underwent allogeneic bone marrow transplantation (alloBMT) at our institution over a period of 4 years. Retrospective analysis of their medical records revealed that a mean age at transplant was 45.2 years. The median time to diagnosis was 7.4 years after transplant. At relapse, four, two, and one patients were classified as having hematologic, major molecular, and cytogenetic relapse, respectively. At imatinib initiation, five had CML in a chronic phase, while one patient was diagnosed as having accelerated phase and blast crisis. All these patients could be evaluated for the therapeutic efficacy. At a mean of follow-up of 1.9 years of therapy, all evaluable patients achieved major molecular response without compromising safety. Consistent with available data, our results indicate that imatinib is safe and effective treatment option for patients with relapse after BMT.